Jordan-based MS Pharma has announced entering into an agreement with mAbxience S.L. to commercialize the firm’s bevacizumab biosimilar in the Middle East and North Africa region.
MS Pharma Partners With Mabxience For Bevacizumab In MENA Region
Follows Agreement With Alvion For Rosuvastatin/Ezetimibe In MENA
Jordan-based MS Pharma has struck a deal with Insud Pharma subsidiary Mabxience to commercialize its bevacizumab biosimilar in the Middle East and North Africa region. The move comes after Mabxience partnered with Zentiva to commercialize bevacizumab in 21 European countries. Meanwhile, MS Pharma has also partnered with Alvion Pharma for rosuvastatin/ezetimibe in the MENA region.
More from Biosimilars
• By
Organon has swelled its immunology biosimilar portfolio after acquiring the US commercial rights to Bio-Thera’s tocilizumab biosimilar from Biogen, which last year decided to retain its interests in biosimilars following a lengthy strategic review.
• By
Alvotech has named two new key executives, while Biosimilars Canada has elected its 2025 leaders and the AAM has welcomed the new FDA commissioner in the US.
Gedeon Richter has filed its Mochida-partnered tocilizumab biosimilar rival to RoActemra with the European Medicines Agency. But with several biosimilars already having won approval, the market could be competitive.
• By
Accord received positive opinions for its Prolia and Xgeva biosimilars at the latest meeting of the EMA’s CHMP. Meanwhile, Celltrion picked up a nod for another Stelara biosimilar, while Rechon Life Science withdrew an application for human insulin.
More from Products
• By
Organon has swelled its immunology biosimilar portfolio after acquiring the US commercial rights to Bio-Thera’s tocilizumab biosimilar from Biogen, which last year decided to retain its interests in biosimilars following a lengthy strategic review.
• By
The US FDA has deemed certain CRO Raptim Research’s in vitro bioequivalence studies as “not acceptable” and raised concerns over its in vivo study methods. Will other agencies follow suit?
• By
Teva should not be able to overturn European fines imposed over a historical “pay-for-delay” arrangement covering Cephalon’s Provigil (modafinil), an advocate general of the CJEU has recommended.